Ganetespib (STA-9090)

Name: Ganetespib (STA-9090)
Brand: Selleck Chemicals
SKU: S1159
Rating: 5 (44 reviews)

For research use only.

Catalog No.S1159

44 publications

Ganetespib (STA-9090) Chemical Structure

CAS No. 888216-25-9

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Selleck's Ganetespib (STA-9090) has been cited by 44 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 10.1038/nature21064

PubMed: 28178232 ( click the link to review the publication )

Cell, 2017, 168(5):856-866

PubMed: 28215707 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):126

PubMed: 33500390 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00221-X

PubMed: 34077750 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00400-1

PubMed: 34525344 ( click the link to review the publication )

Mol Cancer Ther, 2021, 10.1158/1535-7163.MCT-21-0215

PubMed: 34376581 ( click the link to review the publication )

Cancer Biol Med, 2021, j.issn.2095-3941.2020.0262

PubMed: 33764710 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00798-5

PubMed: 34302809 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-020-1860-2

PubMed: 33439458 ( click the link to review the publication )

Cancer Discov, 2020, 10(5):674-687

PubMed: 32213539 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:2997-3011

PubMed: 32308431 ( click the link to review the publication )

Theranostics, 2020, 10(18):8415-8429

PubMed: 32724478 ( click the link to review the publication )

DASH, 2020, None

PubMed: None ( click the link to review the publication )

Nat Commun, 2019, 10(1):402

PubMed: 30679438 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Theranostics, 2019, 9(2):554-572

PubMed: 30809293 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):911

PubMed: 31801945 ( click the link to review the publication )

Endocr Relat Cancer, 2019, 10.1530/ERC-18-0509

PubMed: 30730850 ( click the link to review the publication )

Food Chem Toxicol, 2019, 132:110645

PubMed: 31254591 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2019, 10:487

PubMed: 31379752 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.220871

PubMed: 31439673 ( click the link to review the publication )
ACS Chem Neurosci, 2019, 10(6):2890-2902

PubMed: 31017387 ( click the link to review the publication )

Hepatology, 2019, 69(2):573-586

PubMed: 29356025 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Mol Cell, 2018, 69(4):594-609

PubMed: 29452639 ( click the link to review the publication )

Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(7):e8071

PubMed: 29997244 ( click the link to review the publication )

Mol Cancer Res, 2018, 10.1158/1541-7786

PubMed: 30002191 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29599910 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Nat Commun, 2017, 8(1):422

PubMed: 28871086 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Sci Rep, 2017, 7(1):6420

PubMed: 28743892 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1232

PubMed: 28450729 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 329:282-292

PubMed: 28624441 ( click the link to review the publication )

Oncotarget, 2017, 8(25):41294-41304

PubMed: 28476040 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Hum Mol Genet, 2015, 10.1093/hmg/ddv136

PubMed: 25877301 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1017

PubMed: 25297628 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(5):1015-22

PubMed: 25205430 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Targets

HSP90 ^[1]
(OSA 8 cells)

4 nM

In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. ^[1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. ^[1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. ^[2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. ^[3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.^[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. ^[4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
NCI-H1975	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn\PO\|IhcA>?		NYriXoh4UUN3ME24JI5O	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF2NE[2OUc,OjJzNES2OlU9N2F-
NCI-H1975	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3rJeFQ5KGh?		NXG4SoFOUUN3ME2xOkBvVQ>?	M{ThTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUS0OlY2Lz5{MkG0OFY3PTxxYU6=
Calu-6	NW\WcYdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInscoVKSzVyPU[0JI5O	NITSWYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
Calu-1	NXHMcHVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTV6IH7N	M37h[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H2122	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTV\|IH7N	M1PDR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
A549	M4D1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfTSYhlUUN3ME20N{BvVQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H358	NIfIOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTJ7IH7N	M2jJT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H1734	M1jQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\4S5pKSzVyPUK4JI5O	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H727	NF\RPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nwb2lEPTB;Mkigcm0>	MnPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
COR-L23	MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHlTWM2OD1{MjDuUS=>	NIHjeoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H1792	NH\reHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXx[\|hpUUN3ME2yNEBvVQ>?	MoLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H2009	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDuRnVpUUN3ME2xPUBvVQ>?	NHTUSWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
SK-LU-1	NYXEWFJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPyTWM2OD1zODDuUS=>	NIHrRW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H2212	Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml30TWM2OD1zNzDuUS=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H441	NVTybm0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\xSWdKSzVyPUG0JI5O	M1XQWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H2030	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojsTWM2OD1zMjDuUS=>	M1f3W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H23	NFHrTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTFzIH7N	MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
HOP-62	NGDlflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnt[HpKSzVyPUGxJI5O	M4\ZblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
IA-LM	Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\HOnVKSzVyPUGwJI5O	M3;aXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H460	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPSTlh6UUN3ME24JI5O	NF7TZVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H157	NH76OVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUCxSVZ2UUN3ME23JI5O	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H1355	NIPJWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPKTWM2OD13IH7N	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
VCaP	NGf4W\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;kZ\|BoUUN3ME23JI5O	M1K3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUWyNFA1Lz5{M{G1NlAxPDxxYU6=
LNCaP	M{fSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[zXIZKSzVyPUigcm0>	M3nJXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUWyNFA1Lz5{M{G1NlAxPDxxYU6=
Ramos-RA1	NGHJUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD0TWM2OD15LkSgcm0>	M2LXSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
Karpas-299	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTlwNjDuUS=>	MnjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
Kasumi-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTVwODDuUS=>	NXjkRXR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
CCRF-CEM (2)	M3\vNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLZb2ZKSzVyPUeuNkBvVQ>?	NX64OZl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
CCRF-CEM (1)	M1jpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTF{LkWgcm0>	NGT0SI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
MOLT-4	NEPTemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnMWXZ7UUN3ME2xNE43KG6P	NEXTfI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
RS4;11	NE\hN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\oN\|BYUUN3ME2xN{42KG6P	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN\|MEO3OFE9N2F-
COG-LL-317	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLMOWpRUUN3ME20MlQhdk1?	M2fhbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
NALM-6	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jYSWlEPTB;MUGuO{BvVQ>?	NEnCXYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
CHLA-136	NX3RZ\|ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TITWlEPTB;MkOuNkBvVQ>?	M1fKOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
CHLA-90	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHQfWFKSzVyPUKyMlMhdk1?	NYXtNG93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
NB-EBc1	M4Szcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEm4eI1KSzVyPUG2Mlghdk1?	M2jtVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
NB-1643	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV[3XY96UUN3ME23MlQhdk1?	NFrISJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
SJ-GBM2	NITGbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfNTWM2OD1zMj65JI5O	MnzsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
CHLA-258	NXzaT4VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjpcJJrUUN3ME22MlQhdk1?	NWizWIx2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
CHLA-10	NY\3bHYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjuc2F2UUN3ME21Mlchdk1?	NV\XW5NRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
CHLA-9	Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjkTWM2OD12Lk[gcm0>	M{f4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
TC-71	M{i2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3vdJlYUUN3ME20MlUhdk1?	Mlj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
CHLA-266	M{OxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDoR5JKSzVyPUK3MlEhdk1?	NWLhd4VSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
BT-12	NXL4PY14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXHTWM2OD1zND6zJI5O	NVi4R3RYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
Rh30	M2LMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3Px[WlEPTB;NT62JI5O	M1rCWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
Rh18	MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTZwMjDuUS=>	NWPvfXZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
Rh41	NH;BPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1u0bGlEPTB;MUCuOEBvVQ>?	M1rWVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
RD	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;KTWM2OD16IH7N	MlfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
K033	MofLRZBweHSxc3nzJGF{e2G7	MnzBNVAxKG6P	NX7HRXZ7PzJiaB?=		Mn;Md4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>?	NVruT4ZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
M23	Ml;GRZBweHSxc3nzJGF{e2G7	Moi0NVAxKG6P	NG\kfog4OiCq		NFfycm9{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m\|	MkGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K029	MoHIRZBweHSxc3nzJGF{e2G7	MnPHNVAxKG6P	NVjYV3lSPzJiaB?=		Mn;ad4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>?	MnzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K028	NH7NdFdCeG:ydH;zbZMhSXO\|YYm=	M3XhT\|ExOCCwTR?=	MkfaO\|IhcA>?		NEPlUVd{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m\|	MkDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K008	MWDBdI9xfG:\|aYOgRZN{[Xl?	MUOxNFAhdk1?	NXrVVolMPzJiaB?=		NYHCdYlOe2mpbnnmbYNidnSueTDpcoR2[2W\|IHHwc5B1d3Orcx?=	Mm\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K033	NUGyXYFkTnWwY4Tpc44hSXO\|YYm=	NEnF[mUzPTBibl2=	NEfm[WozPCCq		M37XeYlv\HWlZYOgZUBud2Snc4SgbY5kemWjc3WgbY4hTzFicH;weYxifGmxbh?=	MmrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
M23	NYDHOpV3TnWwY4Tpc44hSXO\|YYm=	NHXDXIgzPTBibl2=	NYq0boZNOjRiaB?=		NH;3dmJqdmS3Y3XzJGcyKGGwZDDHNk9OKGG{cnXzeC=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K029	NEm1fVlHfW6ldHnvckBCe3OjeR?=	NFnE[YEzPTBibl2=	MXOyOEBp		NXLrVW1ucW6mdXPld{BIOSCjcoLld5Q>	NHToVVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K028	M1zqbWZ2dmO2aX;uJGF{e2G7	M1PpZlI2OCCwTR?=	NFXYOoUzPCCq		NHj3ZpdqdmS3Y3XzJGczKGG{cnXzeC=>	NHHKVVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K008	NELCUHpHfW6ldHnvckBCe3OjeR?=	NHPvSYkzPTBibl2=	NWnYXFg{OjRiaB?=		NEjTNHJqdmS3Y3XzJGczKGG{cnXzeC=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K033	M3nXZWNmdGxiVnnhZoltcXS7IFHzd4F6				M2rGTGlEPTB;N{WuOUBvVQ>?	MlLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
M23	NILVZpFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?				NYTQbI9vUUN3ME2zO{42KG6P	NX7pS4lqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
K029	MnTuR4VtdCCYaXHibYxqfHliQYPzZZk>				M3j1WGlEPTB;NE[gcm0>	NHfKOIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K028	NYTH[IFHS2WubDDWbYFjcWyrdImgRZN{[Xl?				MlLPTWM2OD16NDDuUS=>	Mo\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K008	MnPVR4VtdCCYaXHibYxqfHliQYPzZZk>				M2jtSWlEPTB;NkCgcm0>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
H3122	NX7NV2M1S2WubDDWbYFjcWyrdImgRZN{[Xl?	MoHrNE0yODByIH7N	MV63NkBp		NF;INYNKSzVyPUGwJI5O	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{OyOlUoRjJ\|NUOzNlY2RC:jPh?=
H2228	MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mn\TNE0yODByIH7N	NV2yWVNSPzJiaB?=		MVvJR\|UxRTF\|IH7N	NYL2Wop7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|MzPjVpPkKzOVM{OjZ3PD;hQi=>
A1847	NVzHNY5CSXCxcITvd4l{KEG\|c3H5	NFrTc4cyOC1zMECgcm0>	M1LNVlI1NzR6L{eyJIg>		MXnpcoR2[2W\|IHHwc5B1d3OrczD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfGy7	M17rZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUCwNVM3Lz5{M{mwNFE{PjxxYU6=
OVCAR-8	NXKwNVdySXCxcITvd4l{KEG\|c3H5	M2rKVVExNTFyMDDuUS=>	Mn\YNlQwPDhxN{KgbC=>		NGTLemVqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5	NVuzUY1LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFAyOzZpPkKzPVAxOTN4PD;hQi=>
OVCAR-5	NWDtc241SXCxcITvd4l{KEG\|c3H5	MV6xNE0yODBibl2=	NEn4ZVIzPC92OD:3NkBp		NXfMR3VEcW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboTsfS=>	M4XzelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUCwNVM3Lz5{M{mwNFE{PjxxYU6=
SKOV-3	NFfIcHZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NH;sZWwxNTFyMECgcm0>	NIjQXJo4OiCq		M12xU4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	M1TpbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUCwNVM3Lz5{M{mwNFE{PjxxYU6=
A1847	M{X6PWNmdGxiVnnhZoltcXS7IFHzd4F6	Ml3aNE0yODByIH7N	M2jUdFczKGh?		MoTHbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NWX2S5VnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFAyOzZpPkKzPVAxOTN4PD;hQi=>
OVCAR-8	MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MVewMVExODBibl2=	MV[3NkBp		NGqwTWRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NIfIcpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFE{Pid-MkO5NFAyOzZ:L3G+
OVCAR-5	NGPtWFhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NYL4cnFwOC1zMECwJI5O	MmjmO\|IhcA>?		NIjMO2JqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NYq5c49qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFAyOzZpPkKzPVAxOTN4PD;hQi=>
H146	Mn7aSpVv[3Srb36gRZN{[Xl?	NE\OUlk{OCCwTR?=	NVfJfJdwPzJiaB?=		MUPpcoR2[2W\|IIDldpNqe3SnboSgS\|IwVSCyaHHz[UBienKnc4S=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
GLC4	NITGS3NHfW6ldHnvckBCe3OjeR?=	MmDiN\|Ahdk1?	Mn7jO\|IhcA>?		M{HJc4lv\HWlZYOgdIVze2m\|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=>	M3jOclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
H82	MYrGeY5kfGmxbjDBd5NigQ>?	NFvRenQ{OCCwTR?=	M4T5TlczKGh?		NYXHV\|lGcW6mdXPld{Bx\XK\|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1	NVOzZ4NSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
AC3	NHu3Z5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\SVYZKSzVyPUK1Mlkhdk1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H1173	M{HhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXqTWM2OD1zMj62NkBvVQ>?	NFjRcnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
H792	NX;0N251T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTsTWM2OD12NT6wO{BvVQ>?	NI\TbZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
H620	M3y4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fjPWlEPTB;M{KuOlchdk1?	MnTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
N592	NXLQVYpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33Id2lEPTB;MUSuNVIhdk1?	MkT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H526	NGDTfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYm5VYtxUUN3ME2yNU43PCCwTR?=	MnG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H187	NVfqSpZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Pid2lEPTB;MkSuPVkhdk1?	NInjZpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
H146	MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7jVpBKSzVyPUK4MlUyKG6P	NEO0VJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
H128	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjFbW1TUUN3ME22PU42PSCwTR?=	NY\iW4x[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H69	M4TtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTh\|LkO2JI5O	M4PNO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
GLC4	MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TWZmlEPTB;MkCuOFchdk1?	MmrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H82	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nBOmlEPTB;M{CuNlchdk1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
MDA-MB-231	MWTGeY5kfGmxbjDBd5NigQ>?	NHTT[\|EyODBibl2=	NH\ySFAzPCCq		M37mbIlvcGmkaYTzJJRp\SCvaXfyZZRwenliYX7kJIlvfmG\|aY\lJINieGGlaYT5xsA>	M4rDclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUezOVQyLz5{NEG3N\|U1OTxxYU6=
BT-20	MmrUSpVv[3Srb36gRZN{[Xl?	MWqxNFAwOjVyIH7N	NI\WOokzPCCq		M{DoRZJme3WudHXkJIlvKGFiZH;z[U1l\XCnbnTlcpQh\GW\|dHHibYxqgmG2aX;uJI9nKEWJRmKsJGlITi2LUjygUWVVNCCjbnSgR3JCTg>?	NGi2[mg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3N\|U1OSd-MkSxO\|M2PDF:L3G+
MDA-MB-435	NIXvcopHfW6ldHnvckBCe3OjeR?=	MUWxNFAhdk1?	M4S4TFMxKG2rbh?=		NIDUbHVqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2OEK2OUc,OjR{NEiyOlU9N2F-
MDA-MB-231	MYjGeY5kfGmxbjDBd5NigQ>?	NWLLTotZOTByIH7N	MYKzNEBucW5?		NWTIdGZ5cW6qaXLpeJMh[WOldX31cIF1cW:wIH;mJGhKTi1zzsG=	MkDpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEiyOlUoRjJ2MkS4NlY2RC:jPh?=
HCC2998	NHXkO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzub3pzUUN3ME2xNlghdk1?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
SK-CO-1	M1:4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRThzIH7N	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
LS-123	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nudWlEPTB;N{Ogcm0>	M1TFOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
SNU-C2B	NVzCem9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3uTWM2OD12NTDuUS=>	MnT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
LS-1034	M2Swdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEC0W3NKSzVyPUOxJI5O	NE\DZos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
LoVo	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLtXZVKSzVyPUKyJI5O	M3[x[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
COLO-678	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTJzIH7N	M2HhelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
NCI-H747	NYiwS\|Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTF5IH7N	M1rKblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
COLO-205	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jVT2lEPTB;MUSgcm0>	NUHjb\|NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
HCT 116	NWTaOXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\5VHdKSzVyPUG0JI5O	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
HuTu-80	M4rYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3r3[2lEPTB;MUOgcm0>	M33GdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
HCT-15	NHP0WJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRThibl2=	MmD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
SW620	NH3r[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRThibl2=	NF7l[FM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
LS-411 N	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3kVG5[UUN3ME21JI5O	M4TD[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
RKO	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvJTWM2OD12IH7N	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
SW780	NYDKN2pET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTN2NUGgcm0>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
RT4	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV73cVU1UUN3ME2xO\|M{KG6P	MoL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
TCCSUP	Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvwO5RKSzVyPUG0NkBvVQ>?	NVOxbXd1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
MGH-U3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTV\|IH7N	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
HT-1197	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTV\|IH7N	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
5637	NHL5XFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\TbJdKSzVyPUS0JI5O	M2fRflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
35612	NVfvblhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1H6R2lEPTB;M{igcm0>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
KU-19-19	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rEUWlEPTB;M{[gcm0>	NVXiTm1FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
LB831-BLC	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrJTWM2OD1\|NDDuUS=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
UM-UC3	M4j1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7RUYxHUUN3ME2zN{BvVQ>?	MnzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
647-V	M2XSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUGzSnQxUUN3ME2yO{BvVQ>?	MojZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
HT-1376	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrGcZNZUUN3ME2yNUBvVQ>?	NGS1blY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
J82	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTF6IH7N	NX;BTZhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
BFTC	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnL0TWM2OD1zNzDuUS=>	NGrmepE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
SCaBER	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfWOIpKSzVyPUGwJI5O	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
639-V	MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjRU2dKSzVyPUGwJI5O	MoS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
RT112	NHjze\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTlibl2=	MmXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
T24	M4HMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXMTWM2OD15IH7N	NHTlN4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
SW-1710	M3e5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV:w[\|VmUUN3ME22JI5O	M2m5N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
DSH1	NGnEb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGT4PHNKSzVyPU[gcm0>	M3juPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
CAL27	MWDDfZRwgGmlaYT5JGF{e2G7	NGniRZUyOC93MDDuUS=>	Ml\aNlQhcA>?		MXTk[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm=	M1XL[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC1OFMxLz5{NUKwOVQ{ODxxYU6=
Detroit562	MWLDfZRwgGmlaYT5JGF{e2G7	Mn;DNVAwPTBibl2=	MYOyOEBp		M2fpcIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:\|ZTDk[ZBmdmSnboTsfS=>	MmjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEW0N\|AoRjJ3MkC1OFMxRC:jPh?=
FUDA	MUjDfZRwgGmlaYT5JGF{e2G7	M4DSRlExNzVyIH7N	MlPCNlQhcA>?		NUjrV2dW\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6	NF\j[YU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwOVQ{OCd-MkWyNFU1OzB:L3G+
SCC25	NFTW[VBEgXSxeHnjbZR6KEG\|c3H5	M2nIelExNzVyIH7N	MXuyOEBp		MoTG[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyNUSzNEc,OjV{MEW0N\|A9N2F-
HT-29	MmTOSpVv[3Srb36gRZN{[Xl?	NHjFboU2OG6P	MnzCNlQhcA>?	M3XJfmROW09?	MUTpcoR2[2WmIFewM2cyKGG{cnXzeC=>	NYr0W\|gxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTRpPkK1NlExPzl2PD;hQi=>
HCT-116	NFWzZYJHfW6ldHnvckBCe3OjeR?=	NEnucFQ2OG6P	NXPZWXBDOjRiaB?=	M{HGbmROW09?	MkizbY5lfWOnZDDHNE9IOSCjcoLld5Q>	Mn7uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUC3PVQoRjJ3MkGwO\|k1RC:jPh?=
MGC-803	M2PQXmZ2dmO2aX;uJGF{e2G7	MUewMlEuOTByMDDuUS=>	MWmyOEBp		MmXKbY5lfWOnczDHNk9OKGOnbHytZ5lkdGViYYLy[ZN1	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MEiwOUc,OjV3OUC4NFU9N2F-
MKN-28	M2TRUGNmdGxiVnnhZoltcXS7IFHzd4F6	NIDNZ5cxNjFvMUCwNEBvVQ>?	NIHZ[oM4OiCq		MmS3bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	M2X4SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmwPFA2Lz5{NUW5NFgxPTxxYU6=
SGC-7901	NXy3bJJxS2WubDDWbYFjcWyrdImgRZN{[Xl?	NI\3enQxNjFvMUCwNEBvVQ>?	MWO3NkBp		M1fNO4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NGDsNJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NFgxPSd-MkW1PVA5ODV:L3G+
MGC-803	NInJVYxE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MoXNNE4yNTFyMECgcm0>	MYO3NkBp		MoTJbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MnvGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUC4NFUoRjJ3NUmwPFA2RC:jPh?=
MV411	NFz0W3VCeG:ydH;zbZMhSXO\|YYm=	MVSzNE85OC9zNUCvNlUxKG6P	M1zOPFI1NzR6L{eyJIg>		NXPtU4I{cW6mdXPld{Bld3OnIHTldIVv\GGwdDDpcoR2[3Srb36gc4Yh[XCxcITvd4l{	Ml;ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEK1OVAoRjJ3OEiyOVUxRC:jPh?=
HL60	NFOz[ZNCeG:ydH;zbZMhSXO\|YYm=	M3T3Z\|MxNzhyL{G1NE8zPTBibl2=	NFfYSHgzPC92OD:3NkBp		NETMdphqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM>	M2HW[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEiyOVUxLz5{NUi4NlU2ODxxYU6=
TC32	MYnxTHRUKGG\|c3H5				NEnkSG9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	NH7xZYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NVHhWI1YeUiWUzDhd5NigQ>?				NHewZlRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MlvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NUm5S2VZeUiWUzDhd5NigQ>?				NWfkOlZleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	MlPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	MYDxTHRUKGG\|c3H5				MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	M1zOU5FJXFNiYYPzZZk>				MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NXjVO5RoeUiWUzDhd5NigQ>?				M1nrWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	NHHQcHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MmTOdWhVWyCjc4PhfS=>				NWXM[WlueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	M4DYNJFJXFNiYYPzZZk>				NXHUOY1veUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NXjRR\|FCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	MUPxTHRUKGG\|c3H5				M1vUVpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	NIfWRWhyUFSVIHHzd4F6				MU\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NF7NW4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MmmzdWhVWyCjc4PhfS=>				MoDXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MlrwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	MXPxTHRUKGG\|c3H5				MoradWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	M4[0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MXfxTHRUKGG\|c3H5				MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	Mn;WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	MlvZdWhVWyCjc4PhfS=>				NWrxdJI6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK; PubMed: 23418523 PLoS One Downregulation of multiple signaling pathways by ganetespib in melanoma cells.A. Cells were treated with indicated amounts of ganetespib for 24 h. B-RAF and N-RAS mutational status of each cell line is indicated. p27(Kip1) / p21 (Cip1) / Cyclin D1 / Cyclin E / Cyclin B1 / CDK1 / CDK2 / CDK4; PubMed: 23418523 PLoS One Alterations in expression of multiple cell cycle regulating proteins induced by ganetespib. Cells were treated with indicated amounts of ganetespib for 48 h and analyzed by Western blot analysis. Relative expression levels of proteins (treated vs. control䲧疝Ỵ疞㧀疜膉痘  Survivin / Bcl-2 / Bcl-xl / Mcl-1; PubMed: 23418523 PLoS One Effect of ganetespib on the expression of antiapoptotic proteins. Cells were treated with ganetespib for 48 h and analyzed using Western blot analysis. Relative expression levels of proteins are indicated. B-RAF / C-RAF / N-RAS ; PubMed: 23418523 PLoS One Effect of ganetespib on B-RAF, C-RAF and N-RAS expression in melanoma cells.Cells were treated with indicated amounts of ganetespib for 48 h and subjected to Western blot analysis. HER2 / p-STAT3 / BIM ; PubMed: 25077897 Target Oncol NCI-H1975 cells were incubated with the indicated concentrations of ganetespib for 24 h. Cell lysates were analyzed by Western blotting. CDK1 / Cyclin D1 / Cyclin B1 / p27; PubMed: 29717218 Sci Rep Cropped Western blot images of the indicated cell cycle regulators are shown in ganetespib-treated (0–300 nM for 16 hours) BT474 and SKBR3 cells. c-PARP / c-caspase 3 / caspase 8 / c-caspase 8 / caspase 9 / c-caspase 9; PubMed: 29717218 Sci Rep Cropped images of Western blots at the target molecular weights for the indicated apoptotic markers are shown in ganetespib-treated (0, 10, 30, 100, 300 nM for 16 hours) BT474 and SKBR3 cells. ErbB2 / pErbB2 / Src / pSrc / mTOR / pmTOR / Bad / pBad / GSK3 / pGSK3; PubMed: 29717218 Sci Rep Ganetespib inhibits RTK signaling in ErbB2+ breast cancer cells. BT474 and SKBR3 cells were treated with ganetespib (0, 10, 30, 100, or 300 nM) for 16 hours, followed by Western blot analysis (cropped images) of the expression and activation/phosphorylati䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖 Wee1 / p-Wee1 / Chk1 / p-Chk1; PubMed: 27834954 Cell Death Differ Hsp90 inhibition degrades the G2/M checkpoint kinases Wee1 and Chk1. The cells were treated with 200 nM ganetespib and 75 μM carboplatin for 24 h followed by immunoblot analysis. Carboplatin treatment leads to the activation of Chk1, indicated by phospho—䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ	23418523 25077897 29717218 27834954
Growth inhibition assay	Cell viability ; PubMed: 23418523 PLoS One A. Ganetespib reduced viability. Cells were treated with varying amounts of ganetespib for 72 h and subjected to MTS assay. Data are expressed as mean±SD of three independent experiments. B. Mutational status and ganetespib IC50 of cell lines.	23418523

In vivo

Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.^[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: OSA cells
Concentrations: 0.001-1μM
Incubation Time: 5 days
Method: A total of 1.5 × 10³ OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female severe combined immune-deficient (SCID) mice
Dosages: 25 mg/kg/day for 3 days
Administration: Tail vein injection
(Only for Reference)

References

[4] Lin TY, et al. Exp Hematol. 2008, 36(10), 1266-1277.

- Collapse

Solubility (25°C)

In vitro	DMSO	40 mg/mL (109.76 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ganetespib (STA-9090) SDF

Molecular Weight	364.4
Formula	C₂₀H₂₀N₄O₃
CAS No.	888216-25-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02192541	Terminated	Drug: Ziv-Aflibercept\|Drug: Ganetespib	Neoplasms	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	December 2 2014	Phase 1
NCT02008877	Completed	Drug: ganetespib\|Drug: Sirolimus	Malignant Peripheral Nerve Sheath Tumors (MPNST)\|Sarcoma	Sarcoma Alliance for Research through Collaboration\|Synta Pharmaceuticals Corp.\|United States Department of Defense	December 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does this inhibitor inhibit both isoforms of HSP90?
Answer:
We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-AAG (Tanespimycin) : Phase III for Gastrointestinal Stromal Tumors.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (HSP90) Products

Zelavespib (PU-H71) ^New

Zelavespib (PU-H71, NSC 750424) is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER155008 (C07) is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78 (HSPA5, Bip), respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

Features:Displays very low toxicity toward normal cells.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922, VER-52296) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin (NSC 122750)

Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

HSP990 (NVP-HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Ganetespib (STA-9090)